Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has announced an exciting preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to evaluate their drug, pelareorep, in a groundbreaking pancreatic cancer trial. This trial represents a strategic advancement in the treatment of pancreatic cancer, with an innovative trial design aimed at expediting the development process and reducing costs. Promising early results from the GOBLET study show a significant objective response rate, fueling optimism for the upcoming GCAR adaptive trial.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
